Best Penny Stocks to Buy Under $4? 4 For Your Watchlist Right Now
Why these 4 under $4 penny stocks could be worth keeping an eye on
The post Best Penny Stocks to Buy Under $4? 4 For Your Watchlist Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
4 Penny Stocks Under $4 to Watch in October 2021
With October already showing itself to be a strong month for penny stocks, there are plenty of options for investors to take a look at. Ahead of the market open on October 15th, the Dow Jones Industrial Average gained around 220 points, with other large indexes adding similar gains.
In September, retail sales beat out expectations, pushing up by over 0.7%. This beat analyst expectations by over 0.5%. On Thursday, October 14th, the S&P 500 had its best day since early March, shooting up by around 1.7%.
“The banks painted a strong and healthy picture of the U.S. Consumer. Wall Street can’t turn negative on the economy after seeing reserve releases, moderating trading revenue, mixed loan growth, and a consumer willing to take on debt.”Edward Moya, the Senior Analyst at Oanda
All of this shows that we could be headed toward a much brighter economy in the coming months. But, with Covid still hanging around, there is a large degree of uncertainty in the stock market. Considering all of this, let’s take a look at four penny stocks to watch that are under $4 right now.
4 Under $4 Penny Stocks to Add to Your Watchlist
- Progenity Inc. (NASDAQ: PROG)
- Cemtrex Inc. (NASDAQ: CETX)
- Ocean Power Technologies Inc. (NYSE: OPTT)
- The Metals Company (NASDAQ: TMC)
Progenity Inc. (NASDAQ: PROG)
Progenity Inc. is a biotech penny stock that has climbed by a staggering 52% in the past five days and over 115% in the past month. While gains like this do happen with penny stocks, they are always exciting to see. If you’re unfamiliar, Progenity is a company that develops and commercializes molecular testing products. One of its offerings is Innatal, which is for women early in pregnancy to screen for chromosome abnormalities. It also offers Preparent which screens for hereditary cancer in pregnant women. And more recently, the company has begun offering COVID-19 PCR testing as well.
On October 13th, Progenity announced several patents were granted by the United States Patent and Trademark Office. The USPTO issued four patents related to its ingestible technologies for the delivery of therapeutics via the GI tract. Now Progenity’s patent portfolio consists of 96 patent families, including 180 issued and 220 pending applications. This is a big deal and adds to its large bank of intellectual property.
“We believe we hold one of the most robust ingestible device patent portfolios. The addition of these recent patents further strengthens our intellectual property position and underscores our commitment to innovation in advancing therapeutic discovery, development, and delivery.”The interim CEO of Progenity, Eric d’Esparbes
On October 14th, Progenity’s volume was much higher than its average in the market. And, considering its recent gains, we see that PROG stock is trending heavily right now. With this in mind, will you add PROG to your list of penny stocks to watch?
Cemtrex Inc. (NASDAQ: CETX)
Cemtrex Inc. is a penny stock that climbed by over 17% in the last five days. Again, CETX is a trending penny stock right now which is similar to PROG. This company offers tech devices such as Internet of Things products and smart devices. The company also offers browser-based video monitoring systems and analytics-based recognition systems. Additionally, it is engaged in analytics-based cameras, servers, and access control systems.
On October 12th, the company provided an update on its business operations. It announced that its demand has improved as the economy has reopened over the last few months. Its businesses are now returning to their pre-pandemic operations. Because of this, the company is investing more in sales and marketing staff to increase its R&D and drive innovation. It expects its investments to drive top-line growth over the next few years.
“Looking ahead we are highly committed on executing our development roadmap of next-generation high tech products in IoT, AR & VR, as well as in Artificial Intelligence and Machine Vision for security applications.
Our positive outlook for 2022 is driven by a focus on innovation and product development, and by the achievements of our operating brands. We expect an improvement in our business as the pandemic recedes and with our operational investments are well-positioned for long term growth.”The CEO of Cemtrex, Saagar Govil
Since this announcement was made, CETX stock has skyrocketed in the market. The company’s volume is at 58 million compared to an average of 600,000. Noting this info, will CETX make your list of penny stocks to watch?
Ocean Power Technologies Inc. (NYSE: OPTT)
Ocean Power Technologies Inc. is another solid gainer of the past few weeks. Over the last month, shares of OPTT stock have shot up by over 12%. For some context, OPTT is an industrial company that offers various proprietary systems for generating electricity using ocean waves. The company is involved in the development and commercialization of these products. Its PB3 PowerBuoy system is used for use independent of the power grid in remote offshore locations.
[Read More] 4 Hot OTC Penny Stocks To Watch For October 2021
On September 13th, the company announced its fiscal 2022 results. Quarter over quarter, the company reported revenue of $0.3 million compared to $0.2 million. Ocean Power Technologies also announced a lower net loss during this period. This was attributable to a $0.9 million gain on the extinguishment of its PPP loan after the SBA granted its forgiveness and an income tax benefit of $1 million.
“We made great progress during the quarter as we continue our strategic transformation from a research and development product-based company to a data and power services’ and solutions’ provider.”President and CEO of OPTT, Philipp Stratmann
On October 14th, OPTT stock went up by about 0.5% in the market. The company’s volume is also much higher than its market average. With this in mind, will OPTT be on your penny stocks watchlist?
The Metals Company (NASDAQ: TMC)
Electric vehicles have quickly taken a leading position in the stock market this year. With a push toward a “renewable energy future,” everything relating to green, clean, and alternative energy has gained interest. In addition, the broader focus surrounding ESG investing – Environmental, Social, Governance – has also worked its way into the portfolio strategies for some of Wall Street’s top investment firms.
The Metals Company develops low-impact battery metals. Unlike typical recycling companies or mining companies, TMC obtains its raw materials from seafloor polymetallic nodules. Over the last few weeks, the company has begun work testing pilot demonstrations to determine TMC’s path toward a full-scale production plant for battery metals deemed “most critical” to the US by the Biden Administration. These include things like nickel and cobalt.
Another driver of sentiment for TMC has been insider activity. Earlier this month, Form 4s filed show that Director Andrej Karkar and CEO Gerard Barron picked up more shares in company stock. Barron’s 34,000 shares were bought at an average price of $4.41 totaling nearly $150,000. Meanwhile, Karkar’s purchase was considerably larger and to the tune of 2,250,110 at a $4.4442 average – roughly $10 million. With this has come a surge of October momentum.
Which Penny Stocks Are on Your Buy List Right Now?
While we still have half of the month left in October, there is plenty of bullish sentiment to go around. This is marked by large intraday gains, better than expected economic numbers, and dropping Covid cases.
So, if we consider all of this, we see that investors may feel confident in the future of the stock market. However, we are still in a small period of economic recovery. Considering this, which penny stocks are on your buy list right now?economic recovery pandemic covid-19 dow jones sp 500 nasdaq stocks penny stocks otc testing recovery
Luba Greenwood takes the helm at Kojin Therapeutics, steering an all-female C-suite; Alexion R&D chief packs up for change of scenery at VC firm
How rare is it to find a woman leading a micro- or small-cap biotech company? According to a recent survey, it happens less than 6% of the time. And all-female C-suites? Almost unheard of.
But on Thursday, Kojin Therapeutics officially…
How rare is it to find a woman leading a micro- or small-cap biotech company? According to a recent survey, it happens less than 6% of the time. And all-female C-suites? Almost unheard of.
But on Thursday, Kojin Therapeutics officially tapped Luba Greenwood as its first CEO, completing an all-female C-suite. All of the biotech’s senior scientists are women too, as is the scientific co-founder. It’s a moment that Greenwood always believed would come.
“I have always had a positive look that we will have women and minorities in senior positions,” she told Endpoints News Thursday. “It’s wonderful.”
Looking back at her career, Greenwood would separate her experience into buckets. She dipped her toes in the industry in 2004 as an associate at the law firm WilmerHale, where she represented pharmaceutical, biotech and medtech companies, among others. She’s always been interested in science — but it was while studying biology at Brandeis that a professor encouraged her to learn law.
She stayed at WilmerHale for just over seven years, before transitioning to Pfizer as senior counsel for M&A and corporate compliance. She would later work at another Big Pharma, Roche, as VP of global M&A and business development, and at Google’s life sciences research company Verily as head of strategic business development and corporate ventures.
She’s also dabbled in small companies, helping build startups in several spaces, including immunotherapy, women’s health, artificial intelligence, machine learning and microbiome. Most recently, she was a managing partner at the Dana-Farber Cancer Institute’s venture fund, Binney Street Capital, a venture arm she founded to support the development of treatments for incurable cancers.
“Ultimately I realized that innovation comes down to really two things: really amazing science and really amazing people,” she said.
Kojin’s roots trace back to Vasanthi Viswanathan, who was working as a postdoc in Harvard biochemist Stuart Schreiber’s lab when she demonstrated a “vulnerability” in cancer cells that don’t die after treatment.
Most targeted cancer drugs work by inducing cancer cells to undergo apoptosis: a standard, highly regulated form of cellular suicide. To survive, some cells turn off that apoptosis program. But Viswanathan showed, by throwing thousands of molecules at hundreds of drug-resistant or semi-drug-resistant cell lines, that this program relies on the cell churning out an abundance of fatty acids. And she showed that, in doing so, the cells become open to another form of cell death: ferroptosis, where toxins build up and eventually kill the cell.
That work culminated in Kojin, and though it’s still in early stages, the startup landed a $60 million Series A back in June. Since then, it’s probably doubled in size, Greenwood said.
What’s next for the serial entrepreneur? Cementing a positive culture at Kojin. That begins with a collaborative layout at the company’s new facility in Boston’s seaport — for example, no one (not even the CEO) will have a designated office.
“Hopefully you and I will speak in a year and we’ll be in consideration for one of the small best companies to work for,” Greenwood said.
— Nicole DeFeudis
→ AstraZeneca sub Alexion ditched a Phase III study of Ultomiris in August that showed a “lack of efficacy” for ALS after the drug hit its primary endpoint a month earlier in Phase III for generalized myasthenia gravis. But that’s all in the past now for John Orloff, whose next act will be as a venture partner for Agent Capital, a life sciences investment firm founded by Geeta Vemuri. Orloff replaced Martin Mackay — the current CEO of Rallybio — as Alexion’s R&D chief in 2017 after holding the same title at Baxalta and Novelion Therapeutics.
After his departure from Alexion, Orloff also clinched a spot on the board of directors at BenevolentAI.
→ The David Liu-founded gene editing player Prime Medicine, singled out for this year’s Endpoints 11 and backed by bigwigs like ARCH’s Bob Nelsen and GV’s David Schenkein in a supersized $315 million raise, has appointed Ann Lee as chief technical officer. Lee’s career has been dotted with Big Pharma stops, most recently at Bristol Myers Squibb, where she was SVP and head of cell therapy development and operations (CTDO). Lee spent 14 years at Merck Research Laboratories through the 1990s and early 2000s, and in 2005 she joined Genentech as VP of process R&D, later taking on the role of SVP and head of global technical development at Roche.
→ Rita Jain made a speedy exit within months of becoming Immunovant’s CMO in January, but she’s a medical chief again at Chemocentryx, which just notched an approval for its ANCA-associated vasculitis drug Tavneos last week by a razor-thin margin. This appears to be a no-brainer for CEO Thomas Schall and his team: Jain knows Chemocentryx well as a member of the board of directors with the company since March 2019. Before her lightning-quick stay at Immunovant, Jain held the CMO post at Akebia Therapeutics for two years and was AbbVie’s VP of men’s and women’s health and metabolic development.
→ Poseida Therapeutics, which bagged a $3.6 billion nonviral gene therapy deal with Takeda earlier this week, has made a slew of fresh promotions to its leadership team with the appointments of Johanna Mylet (CFO), Devon Shedlock (CSO, cell therapies), Kristin Martin (chief people and administration officer), and Lisa Portale (SVP, regulatory affairs). Mylet hopped aboard the Poseida train in 2015 and most recently served as SVP, finance. Prior to her role with the San Diego-based company, Mylet was with HUYA Bioscience International and Grant Thornton. Shedlock most recently served as Poseida’s SVP of research & development. Shedlock made his way to Poseida after stints at the Perelman School of Medicine and UPenn’s T-Cell Engineering Laboratory.
Meanwhile, Martin formerly served as Poseida’s chief human resources officer and was previously VP of human resources, facilities and IT at Ardea Biosciences. Last, but not least, Portale jumped aboard Poseida in early 2019 as the company’s VP, regulatory affairs. Prior to that role, Portale was with Pfizer, Phenomix Corporation, Neurocrine Biosciences, Medtronic and Perrigo Company.
→ The shift in J&J’s leadership just got more seismic this week with the retirement of chief scientist Paul Stoffels, who will step aside at the end of the year. Stoffels — who’s also the vice chairman of J&J’s executive committee — was the CEO of Virco and chairman of Tibotec when J&J bought both companies in 2002, and he’s been with the multinational ever since, getting elevated to CSO in 2012 and invigorating R&D thereafter. Stoffels would establish Johnson & Johnson Innovation and Johnson & Johnson Global Public Health to further cement his legacy. The Stoffels news comes after CEO Alex Gorsky announced his departure in August, passing the baton to Joaquin Duato and transitioning to the executive chairman post on Jan. 3.
→ IGM Biosciences has been busy with the creation of some new business units to expand on work areas such as autoimmune diseases and infectious diseases. And with those new units, the California-based company has snatched up a trio of experts from Big Pharma to lead them. John Shiver, the former SVP of vaccine R&D at Sanofi Pasteur, is joining IGM as chief strategy officer of its infectious disease unit. His colleague Tong-Ming Fu, who headed Sanofi Pasteur’s vaccine research in North America, will take up the chief scientific officer spot. Meanwhile, the IGM Autoimmunity and Inflammation department will be headed up by Mary Beth Harler, most recently head of immunology and fibrosis development at Bristol Myers Squibb.
→ Emile Nuwaysir, the former CEO of BlueRock Therapeutics, is stepping into the CEO spot at Ensoma — an ambitious and well-backed startup out of Fred Hutch and the University of Washington. In his new role, Nuwaysir will be tasked with making one of the oldest and most elusive goals in cell and gene therapy a reality: reprogramming blood cells with a simple infusion, an approach that could make CAR-T cancer treatments and transformative therapies for sickle cell and other rare blood disorders far safer, more scalable and more accessible. Nuwaysir brings with him experience from his times at NimbleGen Systems, Cellular Dynamics International and Invenra.
→ Ipsen has named Novartis alum Mari Scheiffele EVP and president, specialty care international, and her first day with the French biotech is scheduled for Nov. 1. Scheiffele pivots to Ipsen after spending three years as the general manager of UK & Ireland at Novartis Oncology, and was also part of the leadership in the specialty care business for Novartis Japan. In August, Ipsen strapped on the dealmaking boots by collaborating with Exicure on neuro diseases—namely Huntington’s and Angelman syndrome — for $20 million upfront.
→ On the heels of unloading data from its “off-the-shelf” CAR-T therapy for patients with B cell lymphoma, CRISPR Therapeutics is undergoing a CFO change with Michael Tomsicek’s retirement after four years at the Samarth Kulkarni-led biotech. He’s succeeded by Brendan Smith, ever-so-briefly the CFO at Translate Bio until Sanofi’s purchase of its partner for $3.2 billion in August. Smith wrapped up six years at Pfizer in 2016 as VP, head of business operations for worldwide R&D before joining Boston Consulting Group as a partner. Kulkarni expressed enthusiasm about the safety data for CTX110 with our Jason Mast on Tuesday, but questions remain over durability.
→ Shankar Ramaswamy’s gene therapy joint Kriya Therapeutics, which launched last year and lassoed a $100 million Series B haul led by Jim Momtazee in July, has welcomed Theresa Heah as CMO and president of the new ophthalmology division, Kriya Ophthalmology. Heah, formerly the CMO at AsclepiX and Applied Genetic Technologies Corporation, is a Sanofi and Allergan alum who also was global strategic marketing and tactical brand plan lead for Eylea at Bayer.
→ We have two promotions at Waltham, MA-based Minerva Neurosciences after the arrival of R&D chief Ramana Kuchibhatla, starting with CFO and CBO Geoff Race getting the bump to president. A member of the Nessan Bermingham-chaired board at F-star, Race made the sprint to Minerva as CFO in 2014 and tacked on the CBO title in 2016. He was also the CEO at Funxional Therapeutics before its 2012 acquisition by Boehringer Ingelheim. Next, the CFO role at Minerva is now in the hands of ex-chief accounting officer Frederick Ahlholm, who also came on board in 2014 after being Amarin’s VP of finance and chief accounting officer.
→ Following the appointments of CMO Mia Levy and chief biopharma business officer Sanket Agrawal this summer, Roche’s Foundation Medicine has selected Dymeka Harrison as chief commercial officer. Before her recent position as the strategic marketing head of Abbott Laboratories, Harrison filled a string of sales roles at Thermo Fisher, bioMérieux and Qiagen. Foundation Medicine’s headquarters will move into a 16-story building in Boston’s Seaport District that’s currently under construction, with the space expected to be ready by 2023.
→ Ashley Hall has signed on to be chief development officer at Southern California’s Reneo Pharmaceuticals, a mitochondrial disease biotech that received a $95 million boost in a Series B that Novo Ventures and Abingworth headlined in December 2020. According to an SEC filing, Hall changed roles from chief development officer to chief regulatory officer at Esperion in June, but only had the proverbial cup of coffee at that post before leaving for Reneo. Earlier, Hall was global regulatory lead, specifically for PCSK9 inhibitor Repatha, with Amgen.
→ Following the appointment of chief commercial officer Conley Chee in late September, Syros has tapped Jason Haas as CFO. Before his most recent turn as co-head of Americas, healthcare investment banking for Barclays, Haas also led healthcare investment banking for the Americas at Deutsche Bank. Syros’ RARα agonist tamibarotene is in Phase II for acute myeloid leukemia (Phase II) and in Phase III for higher-risk myelodysplastic syndrome.
→ Citing personal reasons, Noah Rosenberg is on his way out as CMO of Travere Therapeutics, deciding instead on shifting to an executive advisor role that will take effect by the end of the year. Rosenberg, who has been the medical chief since 2018, is a Pfizer and Sanofi vet in medical affairs who previously owned the CMO title at Esperion. Removing all vestiges of “Pharma Bro” Martin Shkreli by erasing the Retrophin name almost a year ago, Travere joined forces with Vifor Pharma last month to commercialize its kidney drug sparsentan, a deal in which Vifor shelled out $55 million upfront.
→ Speaking of Vifor, Lee Heeson (president, international) and Gregory Oakes (president, North America) have also announced their departures for personal reasons, while Molly Painter is about to apply the first brushstrokes to her Vifor canvas as president, US starting Monday. Painter comes to Vifor from Orphazyme, where she held the same post as she will here, and after three years at Shire she became VP, rare disease at Takeda in 2019. Elsewhere, she’s had marketing stints at Lundbeck and Baxalta.
→ Patrick Walsh is jumping over to Immunic, which back in February had its lead drug fail to impress in two separate trials, as CBO. Walsh brings to the table experience from his time at Akebia Therapeutics, where he served as VP of business development. Prior to that stint, Walsh was in corporate development at AVEO Oncology.
→ Clinton Musil is headed for the exits at Catalyst Biosciences, announcing his resignation as CFO of the South San Francisco biotech effective Oct. 29. We had him in this very space when he took the job on July 1, 2020, and the search is on for a replacement; meanwhile, Catalyst controller Seline Miller earns a promotion to SVP, finance and will also be interim chief financial and principal accounting officer.
→ Filing for the $100 million IPO we’re so accustomed to nowadays, solid tumor-focused Xilio Therapeutics has installed Timothy Hunt as chief culture and corporate affairs officer. From 2016-20, Hunt held the role of chief corporate affairs officer at Editas Medicine, and he’s served as Cubist Pharmaceuticals’ SVP of public affairs. Peer Review also notes that, after getting promoted to the position in April, Ronan O’Hagan is out as Xilio’s CSO, according to his LinkedIn page.
→ Raleigh, NC-based RainBio, a gene therapy player concentrating on corneal diseases, has named Gary Sternberg its acting CEO. Sternberg, the founding CEO of Stargardt disease-focused Stargazer Pharmaceuticals, is the ex-CBO at Eleven Biotherapeutics who was therapeutic head of ophthalmic medical affairs for a time at Genentech, taking charge of US medical affairs for anti-VEGF blockbuster Lucentis.
→ Climbing the ranks at allogeneic gamma delta T cell therapy player Adicet Bio, Blake Aftab has been promoted to SVP and CSO. Aftab began serving as the biotech’s VP and head of research in April, and prior to his stint at Adicet, he was VP and head of preclinical science and translational medicine at Atara Biotherapeutics.
→ With Theresa Heah setting off for Kriya and first-year CEO Robert Dempsey at the controls, Baltimore-based eye disease biotech AsclepiX has now brought on Amir Shojaei as CSO and EVP, clinical development. Shojaei was Dempsey’s chief development officer at TearClear and helmed eye-focused TherOptix, which is now led by Aurion Biotech founder Monty Montoya. Prior to these positions, he was therapeutic area head of ophthalmology at Shire and Takeda.
→ San Diego-based Kite cell therapy partner Shoreline Biosciences is bringing on Scott Forrest as CBO. Back in January, we covered his promotion from CBO to CFO at Autobahn Therapeutics. Forrest, who co-founded ARCH-backed BlackThorn Therapeutics, has also served as COO and CFO at Inception Therapeutics.
→ Galera Therapeutics out of Pennsylvania has a pair of new C-suiters, welcoming chief commercial officer Mark Bachleda and chief legal and compliance officer Jennifer Evans Stacey. Bachleda played a key role in the launches of Breyanzi and Abecma at Bristol Myers as VP & US business unit head for the CAR-T franchise. He’s also been VP of sales at Juno Therapeutics and he ended his 15-year association with Amgen in 2017 as the general manager of Amgen Czech Republic. Evans Stacey moves on to Galera after five years as the Wistar Institute’s VP, general counsel, secretary and government relations. Looking to tamp down the effects of radiation, Galera’s lead drug avasopasem manganese is in Phase III for head and neck cancer patients with radiotherapy-induced severe oral mucositis (SOM).
→ Gene Mack has signed on to be CFO of Houston neuro startup Coya Therapeutics, which launched in February with a nothing-too-fancy Series A and the Treg research of Stanley Appel to guide them. The CFO at OncoImmune before Merck purchased it in one of Roger Perlmutter’s final deals, Mack was also the finance lead at OncoImmune spinout OncoC4.
→ Eli Lilly’s saRNA partner MiNA Therapeutics has greeted a quartet of new execs, and tuning up first is SVP of chemistry Troels Koch, the former VP and head of research at Roche Innovation Center Copenhagen. Next, Julia Vassiliadou (VP, clinical operations) makes her way to MiNA after 19 years with GlaxoSmithKline, where she recently served as global head of in-country clinical operations. Also joining Robert Habib’s squad is Ilian Tchakov, MiNA’s VP of clinical development who brings Big Pharma credentials from Lilly, Roche, AstraZeneca and was Eisai’s head of oncology global early clinical development. Lastly, Kevin Fettes (VP, CMC and quality operations) has been a VP in similar capacities with Galena and Dicerna.
→ As Synairgen gets in gear for regulatory submissions on SNG001, its inhaled interferon beta candidate to treat Covid-19, Roche vet Gareth Walters is stepping in as the UK company’s first chief regulatory officer. During his seven years at Chugai Pharmaceuticals, Walters was head of European regulatory affairs and, before joining Synairgen, global regulatory affairs head (research & early development).
→ Joining forces with J&J in a stem cell collaboration they hope can bear fruit in the treatment of acute myeloid leukemia, Vor Biopharma has paved the way for Veit Schmelmer to be SVP of program and alliance management. An 11-year vet in drug development at Takeda — namely Entyvio — Schmelmer was previously the project lead for MGTA-145 at Magenta, and from 2017-19 he was VP of portfolio strategy for Mersana Therapeutics.
→ Steffen Hellmold has been appointed to the newly created role of SVP, business development, data storage at San Francisco-based synbio specialist Twist Bioscience. Before joining Emily Leproust‘s team at Twist, Hellmold was VP of corporate strategic initiatives at Western Digital. He also served as VP of marketing at Everspin Technologies.
→ With a study looming to determine if CRISPR gene editing can cure HIV — earning the FDA’s seal of approval last month — Excision BioTherapeutics has brought in three more staffers. Sara Turken (general counsel) just closed out her three years at Rocket Pharmaceuticals as head of legal, compliance officer & corporate secretary; Manish Anand (SVP, regulatory affairs) has past regulatory experience from such companies as BioMarin, Portola and Cellectis, and since last summer he had been AskBio’s VP of regulatory affairs; and Robert Gunning (VP, controller) comes to Excision from his CFO post at Novartis sub Advanced Accelerator Applications, where he was also head of finance transformation.
→ As Vish Seshadri prepares for his opportunity to take charge as CEO at Abeona, the gene and cell therapy player has recruited Jon Voss as VP, head of quality. The erstwhile EVP of global quality at Cellectis, a position he held since 2019, Voss has also been a quality control exec at Generation Bio and Sarepta. The drug furthest along at Abeona is EB-101 for recessive dystrophic epidermolysis bullosa.
→ Life sciences tech company Cellares has appointed John Tomtishen as VP of operations. Before joining Cellares, Tomtishen was site managing director of Legend Biotech’s corporate headquarters. Over the summer, Cellares nabbed $100 million in funding for its Cell Shuttle and partnered with Poseida as a therapy provider.
→ Ken Song’s RayzeBio, which snagged a nine-figure Series C round in June to bring its total funding to $258 million, has enlisted Genentech alum Rozalyn Littler as VP of regulatory and quality. Littler also brings regulatory experience from Prometheus Laboratories, Heron Therapeutics and Metacrine. One more RayzeBio note: Nektar SVP and executive clinical fellow Mary Tagliaferri now has a seat on a board of directors that also includes Versant’s Jerel Davis and venBio’s Aaron Royston.
→ Longtime Pfizer alum Susan Silbermann has been elected to the board of directors at Perceptive’s LianBio a week after Michael Humphries was named chief scientific advisor. Silbermann, who just retired from Pfizer (a move several of her other colleagues have either made or intend to make), chaired the pharma giant’s Covid-19 task force and had been global president, emerging markets. In addition, J&J vet Jesse Wu has also joined LianBio’s board.
→ Intarcia president and CEO Kurt Graves has been named executive chairman of ionic liquids biotech i2O Therapeutics. Graves, who has helmed and chaired Intarcia since 2012, was also chairman of the board at Radius Health from 2011-20.
→ After signing a $125 million licensing agreement with HealthCare Royalty Partners last month, Spero Therapeutics has added Kathleen Tregoning to its board of directors. Tregoning currently serves as the chief corporate affairs officer at Cerevel. Before joining Cerevel, she held the EVP of external affairs position at Sanofi.
→ Bob Duggan has turned to Ken Clark as the newest board member at Summit Therapeutics a few weeks after the FDA raised objections to the primary endpoint for its C. difficile drug ridinilazole. Clark, who was behind the scenes of AbbVie’s $21 billion deal to buy Duggan’s old company Pharmacyclics, is a partner at Wilson Sonsini Goodrich & Rosati.
→ Using a gene therapy approach for eye diseases and topping off its Series B financing this summer, French biotech Coave Therapeutics — once known as Horama — has added Olivier Danos and Frederic Chereau to its board of directors. Danos is the CSO at Regenxbio, and Chereau has been CEO at LogicBio for the last five years.
→ Emily Rollins is now a member of the board of directors at Science 37, which is doing a SPAC dance after merging with LifeSci Acquisition II Corp. last week. Rollins, who will chair the audit committee at Science 37, is an ex-audit and assurance partner at Deloitte.
→ The new vacant seat on the supervisory board at InteRNA Technologies has been secured by former Aduro Biotech CSO Andrea van Elsas. Van Elsas succeeds Mark Vaeck, who stepped down. Currently, van Elsas is a venture partner with Third Rock Ventures and has previously served in roles at Merck, Organon and BioNovion.emerging markets covid-19 small-cap vaccine treatment fda preclinical genetic therapy japan european uk czech
Hot Penny Stocks to Watch As We Turn the Corner on October
Which penny stocks are you watching as we turn the corner in October?
The post Hot Penny Stocks to Watch As We Turn the Corner on October appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
3 Penny Stocks to Watch in the Second Half of October 2021
After a less than stellar month of trading penny stocks in September, October has brought with it a higher degree of bullish sentiment. And while we don’t know just how long this bullishness will remain, we do know that it’s worth taking advantage of in the meantime. To understand how to make money with penny stocks in 2021, investors need to have a thorough understanding of the current market conditions.
Right now, we have to consider inflation, Covid, and the general air of uncertainty in the stock market. This uncertainty is illustrated by the sizable volatility we witness on a daily basis. Additionally, we can consider which industries could benefit from the current state of the stock market. This includes biotech penny stocks, reopening penny stocks, tech stocks, and energy penny stocks. These are just a few industries that have been trending over the past few weeks.
As always, it’s important to consider that penny stocks are not for everyone. Because they can be so volatile, many investors choose to find more stable stocks to buy. But, those who are looking to take advantage of short-term price movement, often turn to penny stocks for that purpose. So, considering where the economy and stock market are in October 2021, let’s take a look at three hot penny stocks to watch in the second half of the month.
3 Hot Penny Stocks For Your Mid-October Watchlist
- Tellurian Inc. (NASDAQ: TELL)
- Kosmos Energy Ltd. (NYSE: KOS)
- Grom Social Enterprises Inc. (NASDAQ: GROM)
Tellurian Inc. (NASDAQ: TELL)
Tellurian Inc. is an energy penny stock that managed to climb by almost 6% on October 14th. For some context, this company operates in the natural gas industry. Currently, Tellurian is developing a portfolio of natural gas production, liquefied natural gas marketing, and infrastructure assets. These assets include a 27.6 tons per annum LNG terminal facility and an associated pipeline in Louisiana.
Tellurian’s latest financial results were reported in August for the second quarter. The company ended this quarter with $11.9 million in cash and cash equivalents, as well as no borrowing obligations. The company has a balance sheet with $328.2 million in total assets. During the second quarter, Tellurian produced $5.6 million in revenues from natural gas sales. All of these numbers are quite positive for the company, and show solid signs for investors to consider.
“Tellurian’s strengthened balance sheet and commercial success, combined with supportive market fundamentals, enable Driftwood’s continued progression. We exercised our long-term lease option with the Port of Lake Charles and have started on owner’s projects for site preparation.”The President and CEO of Tellurian, Octavio Simoes
In the last six months, shares of TELL stock have shot up by over 95% and YTD by more than double that. With this in mind, will TELL stock make your penny stocks watchlist in October?
Kosmos Energy Ltd. (NYSE: KOS)
Kosmos Energy Ltd. is an oil and gas company based in the United States. The company focuses on exploration and production along the Atlantic Margins. Some of Kosmos’ operating locations include offshore Ghana, Equatorial Guinea, and the U.S. Gulf of Mexico. The company has additional offshore developments in Mauritania and Senegal as well.
On October 13th, Kosmos announced that it has acquired additional interests in Ghana. The company acquired these assets at a compelling valuation with significant enhancement to its five-year plan. Kosmos acquired an 18% interest in the Jubilee field and an 11% interest in the TEN fields in Ghana from Occidental Petroleum. The total purchase price for the interests was $550 million.
“This is a compelling transaction for Kosmos that accelerates our strategic delivery and is expected to provide long-term sustainable cash flow from fields where we have a deep understanding of the value and future upside.”Chairman and CEO of Kosmos Energy, Andrew G. Inglis
On October 14th, shares of KOS stock shot up by over 8.9%, bringing its one-month gain to almost 40%. The company’s volume is also more than three times its average on October 14th which is worth considering. Considering this, will KOS be on your list of penny stocks to watch?
Grom Social Enterprises Inc. (NASDAQ: GROM)
Grom Social Enterprises Inc. is a communications company that offers a variety of services. Primarily, Grom focuses on media, technology, and entertainment content in the United States. Grom operates a social media network targeted at children under the age of 13 years old. Additionally, the company produces animated films, television series, and provides web filtering to schools and government agencies.
On October 7th, the company’s wholly-owned subsidiary Top Draw Animation commenced production on $1 million in new projects at various studios. These assignments are two recurring episodic animated TV series, which have not yet been disclosed. Currently, Top Draw Animation has over 400 artists in its Manila studio in the Philippines.
“Programmers rely heavily on their animated series and Top Draw Animation is prepared and energized to help entertainment companies around the world bring this visually rich brand of storytelling to life. We currently have hundreds of animation experts and artists focused on feeding the growing demand for animated entertainment.”The President of Top Draw, Russell Hicks
In the last month, GROM stock has increased by over 58% with a YTD gain of almost 120%. These numbers are quite substantial, and show why so many investors are interested in GROM stock. Right now, entertainment remains a budding industry considering the pandemic’s effect on at-home content. So, with all of this considered, will GROM stock make your penny stock watchlist right now?
Which Penny Stocks Are on Your Buy List?
Buying penny stocks in 2021 is all about considering what’s going on in the world. Because penny stocks are highly speculative, company and industry-specific events are extremely important to pay attention to.
These events can help to tell you what type of movement a penny stock may see. And if you know where the movement is, making money with penny stocks can be much easier. So, considering all of this, which penny stocks are on your buy list in October 2021?reopening pandemic nasdaq stocks penny stocks oil mexico
The Science Of Propaganda Is Still Being Developed And Advanced
The Bitcoin Rorschach Test
Hot Penny Stocks to Watch As We Turn the Corner on October
Bitcoin Education For Indonesia
Brace For Price Shock: Americans’ Heating Bills To Soar Up To 50% This Winter
Weekly investment update – Stagflation chatter
Bank of Russia to assess Bitcoin holdings volumes as $36B leave banks
Futures Jump On Profit Optimism As Oil Tops $85; Bitcoin Nears $60,000
Sterling hits 3-week high
Why care workers are feeling less valued and leaving the sector after the pandemic
Crypto8 hours ago
The Science Of Propaganda Is Still Being Developed And Advanced
Commodities11 hours ago
The Bitcoin Rorschach Test
Bonds14 hours ago
Bitcoin Education For Indonesia
Government18 hours ago
“Expert” Calls For Denying Life-Saving Hospital Treatment To The Unvaccinated
Spread & Containment2 hours ago
Huge Dock Worker Protests In Italy, Fears Of Disruption, As Covid ‘Green Pass’ Takes Effect
Spread & Containment22 hours ago
‘Animal Crossing: New Horizons’ will get major updates and ‘Happy Home Paradise’ DLC on November 5
Economics23 hours ago
The Phillips Curve: What Does It Tell Us About Inflation?
Government15 hours ago
4 In 10 TSA Employees Remain Unvaccinated As Deadline Looms